Koers Marinus Pharmaceuticals, Inc. Mexican S.E.
Aandelen
MRNS *
US56854Q2003
Farmaceutische producten
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
124 MXN | -2,36% | -.--% | -2,36% |
17/05 | Sectorupdate: Gezondheidszorgaandelen eind van de middag gemengd | MT |
17/05 | Sectorupdate: Gezondheidszorg | MT |
Omzet 2024 * | 39,35 mln. 701 mln. 36,18 mln. | Omzet 2025 * | 58,17 mln. 1,04 mld. 53,48 mln. | Marktkapitalisatie | 81,3 mln. 1,45 mld. 74,75 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -120 mln. -2,14 mld. -110 mln. | Nettowinst (verlies) 2025 * | -77 mln. -1,37 mld. -70,79 mln. | EV/omzet 2024 * | -1,17 x |
Nettoliquiditeiten 2024 * | 127 mln. 2,27 mld. 117 mln. | Nettoliquiditeiten 2025 * | 54,53 mln. 972 mln. 50,13 mln. | EV/omzet 2025 * | 0,46 x |
K/w-verhouding 2024 * |
-0,75
x | K/w-verhouding 2025 * |
-1,43
x | Werknemers | 166 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,02% |
Recentste transcriptie over Marinus Pharmaceuticals, Inc.
1 dag | -2,36% | ||
3 maanden | -2,36% | ||
6 maanden | -4,62% | ||
Lopend jaar | -2,36% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05-09-18 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 12-04-21 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 06-11-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 01-12-08 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05-09-18 |
Elan Ezickson
BRD | Director/Board Member | 60 | 12-12-19 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+42,26% | 748 mld. | |
+34,11% | 598 mld. | |
-6,21% | 356 mld. | |
+18,11% | 325 mld. | |
+4,35% | 283 mld. | |
+17,15% | 245 mld. | |
+9,05% | 211 mld. | |
-4,13% | 209 mld. | |
+1,81% | 166 mld. |
- Beurs
- Aandelen
- Koers MRNS
- Koers MRNS *